Clinical Papers

Selected Publications, Conference Presentations and Abstracts

Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.” Lazzari, Chiara MD; Spreafico, Anna MD; Bachi, Angela PhD; Roder, Heinrich PhD; Floriani, Irene PhD; Garavaglia, Daniela PhD; Cattaneo, Angela PhD; Grigorieva, Julia PhD‡; Viganò, Maria Grazia MD; Sorlini, Cristina MD; Ghio, Domenico MD; Tsypin, Maxim PhD; Bulotta, Alessandra MD; Bergamaschi, Luca MD*; Gregorc, Vanesa MD; JTO 2012 Jan, 7(1): 40-48

“Serum Proteomics Classifies Outcome in Renal Cell Carcinoma (RCC) Patients Receiving Sunitinib and Erlotinib.” Kyle Robinson, Joanna Roder, Brendan D. Curti, David I. Quinn, John M. Strother, Julia Grigorieva, Heinrich Roder, Christopher W. Ryan. 2011 10th International Kidney Cancer Symposium

“Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.” Amann, J.M., Lee ,J.W., Roder, H., Brahmer, J., Gonzalez, A., Schiller, J.H., Carbone, D.P. J Thorac Oncol. 2010 Feb;5(2):169-78.

“Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients“, Chung, C.H., Seeley, E.H., Roder, H., Grigorieva, J., Tsypin, M., Roder, J., Burtness, B.A., Argiris, A., Forastiere, A.A., Gilbert, J., Murphy, B., Caprioli, R.M., Carbone, D.P., Cohen, E.E. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. (Epub 2010 Jan 19)

“VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab”, J. S. Salmon, T. P. Dang, D. Billheimer, H. Roder, J. Grigorieva, M. Tsypin, R. S. Herbst, A. S. Tsao, H. Tran, D. P. Carbone, 2008 ASCO Annual Meeting, Chicago, IL 30 May – 03 June 2008. J Clin Oncol 26: 2008 (May 20 suppl; abstr 8008)

“Detection of serum proteomic profile predictive for epidermal growth factor receptor tyrosine kinase inihibitors (EGFR-TKIs) in 1st line chemotherapy responders”, C. Belli, A. Spreafico, M. G. Viganò, C. Lazzari, E. Roca, E. Villa, H. Roder, J. Grigorieva, M. Tsypin, V. Gregorc., 2008 ASCO Annual Meeting, Chicago, IL 30 May – 03 June 2008. J Clin Oncol 26: 2008 (May 20 suppl; abstr 8091)

“Changes in serum proteomic profile of non-small cell lung cancer (NSCLC) patients during therapy with epidermal growth factor receptor tirosine kinase inhibitors (EGFR-TKIs): Preliminary report”, A. Spreafico, J. Grigorieva, A. Cattaneo, C. Belli, M. Tsypin, H. Roder, M. Giovannini, M. Alessio, V. Gregorc, A. Bachi., 2008 ASCO Annual Meeting, Chicago, IL 30 May – 03 June 2008. J Clin Oncol 26: 2008 (May 20 suppl; abstr 19034)

“Resistance to EGFR TKIs and Serum Proteomic Profile In NSCLC Patients (abst. 227O)”, V. Gregorc, A. Spreafico, C. Belli, M. Giovannini, M.G. Vigano, H. Roder, D. Ghio, J. Grigorieva, E. Villa, A. Bachi., 33rd ESMO Congress, Stockholm, 2008

“The Association Between Proteomic Profile Detected Before 2nd/3rd line EGFR-TKIs and Response to 1st line Chemotherapy (abst. 277P)”, C. Belli, A. Spreafico, M. Giovannini, M.G. Vigano, C. Lazzari, E. Roca, H. Roder, J. Grigorieva, E. Villa, V. Gregorc., 33rd ESMO Congress, Stockholm, 2008

“Proteomic Biomarkers in Breast Cancer by Laser Capture Microdissection and MALDI MS”, Sanders Melinda E., Dias Eduardo C., Xu Baogang J., Mobley James A., Billheimer Dean, Roder Heinrich, Grigorieva Julia, Dowsett Mitchell, Arteaga Carlos, Caprioli Richard, Journal of Proteome Research, 2008 Apr;7(4):1500-7

“An algorithm that predicts outcome for EGFR TKI therapy has no prognostic association in surgically treated adenocarcinoma lung cancer patients”, A. Spreafico, R. Dziadziuszko, H. Roder, M. Duncan, J. Grigorieva, M. Tsypin, S. Hunsucker, J. Jassem, P. A. Bunn Jr., F. R. Hirsch., 1st European Lung Cancer Conference, 23-26 April 2008, Geneva, Switzerland

“A proteomic algorithm that predicts outcome for EGFR TKI therapy has no prognostic association in surgically treated adenocarcinoma lung cancer patients”, A. Spreafico, R. Dziadziudsko, H. Roder, M. W. Duncan, J. Grigorieva, M. Tsypin, S. W. Hunsucker, P. A. Bunn Jr., F. R. Hirsch, 8th Targeted Therapy of Lung Cancer Meeting, Santa Monica, California February 21-23, 2008

“Longitudinal analysis of serum proteomic profile in NSCLC patients treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs)”, Anna Spreafico, Angela Bachi, Heinrich Roder, Angela Cattaneo, Julia Grigorieva, Carmen Belli, Chiara Lazzari, Maxim Tsypin, Eugenio Villa, Vanesa Gregorc, 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology

“Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study”, Taguchi Fumiko, Solomon Benjamin, Gregorc Vanesa, Roder Heinrich, Gray Robert, Kasahara Kazuo, Nishio Makoto, Brahmer Julie, Spreafico Anna, Ludovini Vienna, Massion Pierre P., Dziadziuszko Rafal, Schiller Joan, Grigorieva Julia, Tsypin Maxim, Hunsucker Stephen W., Caprioli Richard, Duncan Mark W., Hirsch Fred R., Bunn, Paul A. Jr., Carbone David P., Journal of the National Cancer Institute 2007 99(11):838-846

“Serum Proteomic Classifier for Predicting Response to Epidermal Growth Factor Receptor Inhibitor Therapy: Have We Built a Better Mousetrap?”, Tsao Ming-Sound, Liu Geoffrey, Shepherd Frances A., Journal of the National Cancer Institute 2007 99(11):826-827

“Prediction of benefit from EGFR TKIs by proteomic analysis of pretreatment serum: M06-03″, Taguchi, Fumiko; Solomon, Benjamin; Gregorc, Vanesa; Roder, Heinrich; Gray, Robert; Kasahara, Kazuo; Nishi, Makoto; Brahmer, Julie; Spreafico, Anna; Ludovini, Vienna; Massion, Pierre P.; Dziadziuszko, Rafal; Schiller, Joan; Grigorieva, Julia; Tsypin, Maxim; Hunsucker, Stephen W.; Caprioli, Richard; Duncan, Mark W.; Hirsch, Fred R.; Bunn, Paul A. Jr.; Carbone, David P., Journal of Thoracic Oncology. 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007. 2(8) Supplement 4:S167-S168, August 2007